Progress in oncolytic viruses modified with nanomaterials for intravenous application.

Humans Oncolytic Viruses / physiology Neoplasms / therapy Oncolytic Virotherapy Immunotherapy
Oncolytic virus drug delivery intravenous application nanomaterials tumor treatment

Journal

Cancer biology & medicine
ISSN: 2095-3941
Titre abrégé: Cancer Biol Med
Pays: China
ID NLM: 101588850

Informations de publication

Date de publication:
24 Nov 2023
Historique:
medline: 4 12 2023
pubmed: 27 11 2023
entrez: 27 11 2023
Statut: ppublish

Résumé

In oncolytic virus (OV) therapy, a critical component of tumor immunotherapy, viruses selectively infect, replicate within, and eventually destroy tumor cells. Simultaneously, this therapy activates immune responses and mobilizes immune cells, thereby eliminating residual or distant cancer cells. However, because of OVs' high immunogenicity and immune clearance during circulation, their clinical applications are currently limited to intratumoral injections, and their use is severely restricted. In recent years, numerous studies have used nanomaterials to modify OVs to decrease virulence and increase safety for intravenous injection. The most commonly used nanomaterials for modifying OVs are liposomes, polymers, and albumin, because of their biosafety, practicability, and effectiveness. The aim of this review is to summarize progress in the use of these nanomaterials in preclinical experiments to modify OVs and to discuss the challenges encountered from basic research to clinical application.

Identifiants

DOI: 10.20892/j.issn.2095-3941.2023.0275 PMID: 38009779 PMC: PMC10690878
pubmed: 38009779
pii: j.issn.2095-3941.2023.0275
doi: 10.20892/j.issn.2095-3941.2023.0275
pmc: PMC10690878
doi:
pii:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : National Key R&D Program of China
ID : 2021YFA0909900, X. Z.
Organisme : National Key R&D Program of China
ID : 2022YFC2403401, F. L.
Organisme : National Natural Science Foundation of China
ID : 32222045
Organisme : National Natural Science Foundation of China
ID : 32171384, X. Z.
Organisme : National Natural Science Foundation of China
ID : 82073368, F. L.
Organisme : Liaoning Revitalization Talents Program
ID : XLYC2007071, F. L.
Organisme : Top-notch Talents Project of 2022 "Kunlun Yingcai Advanced Innovation and Entrepreneurship" in Qinghai Province (Y. X.)

Informations de copyright

Copyright © 2023 Cancer Biology & Medicine.

Déclaration de conflit d'intérêts

No potential conflicts of interest are disclosed.

Références

Nano Lett. 2019 May 8;19(5):2993-3001
pubmed: 30964695
Nat Rev Drug Discov. 2019 Sep;18(9):689-706
pubmed: 31292532
Cancer Gene Ther. 2022 Oct;29(10):1321-1331
pubmed: 35444290
Biotechnol Adv. 2021 May-Jun;48:107727
pubmed: 33677025
Adv Drug Deliv Rev. 2020;156:40-64
pubmed: 32735811
Acta Biomater. 2015 Dec;28:86-98
pubmed: 26365317
J Control Release. 2018 Aug 10;283:223-234
pubmed: 29864473
Adv Cancer Res. 2012;115:39-67
pubmed: 23021241
Nat Rev Drug Discov. 2021 Feb;20(2):101-124
pubmed: 33277608
Biomater Sci. 2020 May 6;8(9):2472-2480
pubmed: 32196028
Biomaterials. 2021 Jan;268:120597
pubmed: 33360074
Biomaterials. 2009 Feb;30(4):658-64
pubmed: 19007981
Cancer Biol Med. 2023 May 2;20(4):
pubmed: 37144580
ACS Nano. 2017 Nov 28;11(11):11584-11593
pubmed: 29045127
Hum Gene Ther. 2008 Dec;19(12):1369-82
pubmed: 18778197
Drug Deliv. 2018 Nov;25(1):1740-1745
pubmed: 30241446
J Control Release. 2020 Jun 10;322:209-216
pubmed: 32194174
Nano Lett. 2022 Jun 22;22(12):5055-5064
pubmed: 35583490
Nat Rev Microbiol. 2008 Jul;6(7):529-40
pubmed: 18552863
Adv Drug Deliv Rev. 2021 Jul;174:30-52
pubmed: 33845040
J Control Release. 2016 Aug 10;235:379-392
pubmed: 27302248
Hum Gene Ther. 2009 Sep;20(9):975-88
pubmed: 19469693
Curr Gene Ther. 2011 Aug;11(4):307-20
pubmed: 21453277
Nat Rev Neurol. 2019 Jan;15(1):53-58
pubmed: 30315270
Gene Ther. 2005 Apr;12(7):579-87
pubmed: 15647765
Biomaterials. 2011 Aug;32(22):5158-66
pubmed: 21531456
Mol Ther Oncolytics. 2016 Nov 02;3:16022
pubmed: 27847861
Biomacromolecules. 2015 Jan 12;16(1):87-96
pubmed: 25400213
J Control Release. 2018 Feb 10;271:60-73
pubmed: 29273320
Hum Gene Ther. 2005 Dec;16(12):1439-51
pubmed: 16390275
Biomaterials. 2010 Mar;31(7):1865-74
pubmed: 19962189
Neurology. 2018 May 22;90(21):964-973
pubmed: 29695598
J Control Release. 2012 Jul 20;161(2):505-22
pubmed: 22353619
Transl Res. 2021 Nov;237:98-123
pubmed: 33905949
Mol Pharm. 2011 Jun 6;8(3):673-82
pubmed: 21510701
J Clin Invest. 2019 Mar 4;129(4):1407-1418
pubmed: 30829653
Mol Pharm. 2019 Feb 4;16(2):779-785
pubmed: 30604617
Int J Pharm. 2018 Dec 1;552(1-2):437-442
pubmed: 30308276
J Control Release. 2013 Aug 10;169(3):257-65
pubmed: 23562633
Gene Ther. 2009 Dec;16(12):1395-404
pubmed: 19641532
Nat Rev Clin Oncol. 2020 Jan;17(1):49-64
pubmed: 31595049
Pharm Res. 2002 Oct;19(10):1389-99
pubmed: 12425455
Adv Healthc Mater. 2020 Jul;9(13):e1901358
pubmed: 32424996
Angew Chem Int Ed Engl. 2019 Jul 15;58(29):9866-9870
pubmed: 30990942
J Control Release. 2008 Dec 18;132(3):171-83
pubmed: 18582981
Semin Cancer Biol. 2021 Feb;69:190-199
pubmed: 31446004
J Control Release. 2010 Nov 20;148(1):75-82
pubmed: 20637814
J Control Release. 2016 Sep 10;237:78-88
pubmed: 27388756
Sci Rep. 2017 Oct 26;7(1):14177
pubmed: 29074882
Biofouling. 2004 Aug-Oct;20(4-5):189-201
pubmed: 15621640
Endocr Rev. 2021 May 25;42(3):354-373
pubmed: 33480983
Bioconjug Chem. 2015 Aug 19;26(8):1818-29
pubmed: 26158495
Chem Soc Rev. 2016 Mar 7;45(5):1432-56
pubmed: 26771036
Ann Biomed Eng. 2013 Jan;41(1):53-67
pubmed: 22878680
Blood. 2019 Jan 31;133(5):389-398
pubmed: 30559264
J Control Release. 2019 Jul 10;305:75-88
pubmed: 31071373
Pharmaceutics. 2021 Jun 24;13(7):
pubmed: 34202714
J Drug Target. 2007 Aug-Sep;15(7-8):546-51
pubmed: 17671901
Adv Colloid Interface Sci. 2021 Aug;294:102451
pubmed: 34098385
Theranostics. 2017 Aug 23;7(15):3667-3689
pubmed: 29109768
Eur J Pharm Biopharm. 2015 Oct;96:96-105
pubmed: 26212785
Br J Cancer. 2019 Jul;121(2):101-108
pubmed: 31231121
Adv Drug Deliv Rev. 2021 Sep;176:113851
pubmed: 34224787
Mol Pharm. 2010 Feb 1;7(1):105-15
pubmed: 19968324
Biomaterials. 2011 Dec;32(35):9536-45
pubmed: 21959008
J Immunother Cancer. 2018 Dec 4;6(1):140
pubmed: 30514385
Nat Commun. 2023 May 22;14(1):2933
pubmed: 37217527
J Gene Med. 2008 Apr;10(4):400-11
pubmed: 18220318
J Control Release. 2022 Jul;347:211-236
pubmed: 35533946
Adv Sci (Weinh). 2021 Aug;8(16):e2100876
pubmed: 34085415
Int J Nanomedicine. 2006;1(3):297-315
pubmed: 17717971
Adv Drug Deliv Rev. 2021 Jun;173:349-373
pubmed: 33831477
Molecules. 2018 Apr 14;23(4):
pubmed: 29662019
Trends Biotechnol. 2018 Jul;36(7):713-728
pubmed: 29525137
Int J Pharm. 2017 May 30;524(1-2):238-247
pubmed: 28389364
Lancet. 2002 Mar 9;359(9309):824-30
pubmed: 11897280
J Control Release. 2019 Jan 28;294:165-175
pubmed: 30557650
Adv Mater. 2022 Jan;34(2):e2105063
pubmed: 34611948
Acta Pharm Sin B. 2018 Jan;8(1):85-96
pubmed: 29872625
J Control Release. 2018 Jan 10;269:225-234
pubmed: 29154976
Clin Cancer Res. 2021 Jun 1;27(11):2979-2988
pubmed: 33526422
Adv Healthc Mater. 2019 Mar;8(6):e1801002
pubmed: 30450761
Int J Nanomedicine. 2007;2(4):595-607
pubmed: 18203427
Biomaterials. 2018 Dec;185:13-24
pubmed: 30216806
Cancer Biol Med. 2023 May 5;20(5):
pubmed: 37144620
Mol Ther. 2000 Oct;2(4):302-17
pubmed: 11020345
Biomed Res Int. 2014;2014:180549
pubmed: 24772414
Gene Ther. 2001 Mar;8(5):341-8
pubmed: 11313809
J Control Release. 2011 Oct 30;155(2):317-25
pubmed: 21699929
Polymers (Basel). 2020 Feb 02;12(2):
pubmed: 32024289
Adv Drug Deliv Rev. 2020;156:80-118
pubmed: 32980449
Mol Ther. 2005 Jan;11(1):66-79
pubmed: 15585407
Hum Gene Ther. 2002 Oct 10;13(15):1887-900
pubmed: 12396620
Clin Infect Dis. 2019 May 2;68(Suppl 4):S260-S274
pubmed: 31222253
Acta Biomater. 2021 Jun;127:24-40
pubmed: 33812076
Adv Drug Deliv Rev. 2020;154-155:102-122
pubmed: 32650041
Adv Drug Deliv Rev. 2021 Nov;178:113974
pubmed: 34530015
Mol Ther. 2008 Jan;16(1):154-62
pubmed: 17848961
Adv Healthc Mater. 2022 Feb;11(4):e2101979
pubmed: 34788898
JAMA Oncol. 2017 Jun 01;3(6):841-849
pubmed: 27441411
Chem Rev. 2016 Mar 9;116(5):2826-85
pubmed: 26799741
Mol Ther Oncolytics. 2021 Mar 17;21:47-61
pubmed: 33869742
J Immunother Cancer. 2020 Oct;8(2):
pubmed: 33037117
J Immunother Cancer. 2020 Oct;8(2):
pubmed: 33046622
Mol Ther. 2017 May 3;25(5):1107-1116
pubmed: 28392162
Acta Biomater. 2019 Oct 1;97:93-104
pubmed: 31386928
Mol Ther. 2017 Jul 5;25(7):1476-1490
pubmed: 28274797
Acc Chem Res. 2016 Jan 19;49(1):96-105
pubmed: 26642085
J Control Release. 2022 Aug;348:127-147
pubmed: 35660636
Mol Ther Oncolytics. 2021 Jan 26;20:399-409
pubmed: 33614920
Biomaterials. 2014 Nov;35(35):9554-61
pubmed: 25154663
J Pharm Investig. 2018;48(2):143-151
pubmed: 30680248
Macromolecules. 2016 Apr 26;49(8):2928-2941
pubmed: 27134311
Nat Rev Clin Oncol. 2021 Sep;18(9):558-576
pubmed: 34006998
Mol Ther Oncolytics. 2016;3:
pubmed: 26900598
J Hematol Oncol. 2021 Apr 16;14(1):63
pubmed: 33863363
J Liposome Res. 2003 May;13(2):187-97
pubmed: 12855112
Int J Pharm. 2021 Mar 15;597:120271
pubmed: 33548365
J Virol. 2001 May;75(10):4792-801
pubmed: 11312351
Mol Ther. 2018 Jun 6;26(6):1414-1422
pubmed: 29703699
Mol Ther. 2001 Nov;4(5):447-53
pubmed: 11708881
Biomaterials. 2015 Feb;41:53-68
pubmed: 25522965
Theranostics. 2020 Feb 3;10(6):2744-2758
pubmed: 32194832
Biomaterials. 2011 Dec;32(35):9328-42
pubmed: 21924767
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
J Hematol Oncol. 2020 Jun 29;13(1):84
pubmed: 32600470
J Control Release. 2021 Apr 10;332:517-528
pubmed: 33675877
Annu Rev Phys Chem. 2011;62:645-68
pubmed: 21219151
Nat Rev Immunol. 2018 Aug;18(8):498-513
pubmed: 29743717
Adv Drug Deliv Rev. 2018 May;130:73-89
pubmed: 30012492
Theranostics. 2019 Oct 17;9(26):8001-8017
pubmed: 31754377
J Nanobiotechnology. 2021 May 29;19(1):159
pubmed: 34051806
Cells. 2021 Jul 26;10(8):
pubmed: 34440666
BMC Biomed Eng. 2019 Jul 1;1:17
pubmed: 32903299
J Control Release. 2019 Jul 10;305:194-209
pubmed: 31121278
Adv Drug Deliv Rev. 2020 Jan 1;153:87-108
pubmed: 32497707
J Control Release. 2016 Jun 10;231:2-16
pubmed: 26951927
Theranostics. 2017 Jan 1;7(2):319-328
pubmed: 28042337
Biomacromolecules. 2015 Jul 13;16(7):2132-43
pubmed: 26096567
PLoS One. 2014 Jan 27;9(1):e82716
pubmed: 24475024
Adv Healthc Mater. 2018 Jan;7(1):
pubmed: 29171928
Chem Rev. 2021 Feb 24;121(4):2109-2146
pubmed: 33460327
Hum Gene Ther. 1999 May 20;10(8):1349-58
pubmed: 10365665
Nano Lett. 2019 Nov 13;19(11):8002-8009
pubmed: 31626554
Gene Ther. 2004 Aug;11(16):1256-63
pubmed: 15215884
Bioimpacts. 2011;1(1):23-30
pubmed: 23678404
Adv Drug Deliv Rev. 2012 Jun 1;64(8):720-9
pubmed: 22212901
Biosci Rep. 2002 Apr;22(2):197-224
pubmed: 12428901
BioDrugs. 2022 Sep;36(5):667-672
pubmed: 36098872
J Control Release. 2015 May 10;205:134-43
pubmed: 25575865
Pharmacol Ther. 2020 Sep;213:107586
pubmed: 32479843
Ther Deliv. 2015 Jan;6(1):41-58
pubmed: 25565440
Nat Rev Drug Discov. 2015 Sep;14(9):642-62
pubmed: 26323545
Nat Rev Nephrol. 2018 Jan;14(1):48-56
pubmed: 29062142
J Natl Cancer Inst. 2013 Nov 20;105(22):1701-10
pubmed: 24168971
Prog Lipid Res. 2021 Apr;82:101096
pubmed: 33831455

Auteurs

Liting Chen (L)

Department of Surgical Oncology and General Surgery, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, The First Affiliated Hospital of China Medical University, Shenyang 110001, China.
Phase I Clinical Trials Center, Ministry of Education, The First Affiliated Hospital of China Medical University, Shenyang 110102, China.
CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China.

Zhijun Ma (Z)

Department of General Surgery, Panjin People's Hospital, Panjin 124221, China.

Chen Xu (C)

Department of Surgical Oncology and General Surgery, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, The First Affiliated Hospital of China Medical University, Shenyang 110001, China.
Phase I Clinical Trials Center, Ministry of Education, The First Affiliated Hospital of China Medical University, Shenyang 110102, China.
CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China.

Youbang Xie (Y)

Department of Hematology and Rheumatology, Qinghai Provincial People's Hospital, Xining 810007, China.

Defang Ouyang (D)

State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences (ICMS), University of Macau, Macau 999078, China.

Shuhui Song (S)

Department of Surgical Oncology and General Surgery, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, The First Affiliated Hospital of China Medical University, Shenyang 110001, China.
Phase I Clinical Trials Center, Ministry of Education, The First Affiliated Hospital of China Medical University, Shenyang 110102, China.

Xiao Zhao (X)

CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China.
Center of Materials Science and Optoelectronics Engineering, University of Chinese Academy of Sciences, Beijing 100049, China.
IGDB-NCNST Joint Research Center, Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China.
ORCID: 0000-0002-4504-5670

Funan Liu (F)

Department of Surgical Oncology and General Surgery, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, The First Affiliated Hospital of China Medical University, Shenyang 110001, China.
Phase I Clinical Trials Center, Ministry of Education, The First Affiliated Hospital of China Medical University, Shenyang 110102, China.
ORCID: 0000-0003-4762-8279

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Progress in oncolytic viruses modified with...
questionsmedicales.fr › Virus › Virus oncolytiques › Progress in oncolytic viruses modified with...
questionsmedicales.fr › Tumeurs › Progress in oncolytic viruses modified with...
questionsmedicales.fr › Thérapeutique › Biothérapie › Thérapie virale de cancers › Progress in oncolytic viruses modified with...
questionsmedicales.fr › Thérapeutique › Biothérapie › Immunothérapie › Progress in oncolytic viruses modified with...